MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$6,638K
Free Cash flow
-$19,295K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Accounts payable and other accru...
Refundable research income tax c...
Others
Negative Cash Flow Breakdown
Effect of exchange rate changes ...
Accounts receivable
Deferred revenues
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-30,995
-37,419
-34,930
-50,583
Impairment of long-lived assets
-
13,235
0
0
Depreciation and amortization
719
959
989
2,013
Amortization in operating lease right-of-use assets
158
924
909
1,808
Stock-based compensation
992
2,130
2,127
4,822
Accretion of discount on marketable securities
-
-
0
0
Gain on sale of assets classified as held for sale
-
0
-
-
Deferred income tax benefit
0
-
0
-
Other
0
3
0
-35
Interest receivable
-
-
0
0
Accounts receivable
502
-152
151
-154
Prepaid expenses and other assets
-1,201
-4,055
1,836
1,389
Refundable research income tax credits
-4,525
0
0
0
Accounts payable and other accrued liabilities
4,936
-1,506
3,999
301
Other non-current liabilities
-
-397
15
30
Accrued compensation and employee benefits
630
572
1,717
764
Lease liabilities
-449
-448
-1,337
-2,262
Deferred revenues
-497
-6,657
0
-
Net cash used in operating activities
-19,282
-24,403
-28,498
-44,307
Maturities of marketable securities
-
0
0
0
Proceeds from sale of marketable securities
-
0
0
0
Proceeds from sale of assets classified as held for sale
-
0
0
0
Purchases of property and equipment
13
14
64
24
Net cash used in investing activities
-13
-14
-64
-24
Proceeds from issuance of common stock under employee stock purchase plan
-
164
1
179
Proceeds from issuance of common stock, net of offering expenses
23,346
0
-106
21,589
Proceeds from at-the-market offering, net of offering expenses
3,732
14,982
19,576
17,627
Taxes paid related to net share settlement of equity awards
379
349
267
2,647
Net cash provided by financing activities
26,699
14,797
19,204
36,748
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
-766
40
42
4,009
Net increase (decrease) in cash, cash equivalents, and restricted cash
6,638
-9,580
-9,316
-3,574
Cash, cash equivalents, and restricted cash, beginning of period
20,948
30,528
43,418
-
Cash, cash equivalents, and restricted cash, end of period
27,586
20,948
30,528
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock, net of...
$23,346K
Proceeds from
at-the-market offering, net of...
$3,732K
Net cash provided by
financing activities
$26,699K
Canceled cashflow
$379K
Net increase
(decrease) in cash, cash...
$6,638K
Canceled cashflow
$20,061K
Taxes paid related to
net share...
$379K
Accounts payable and
other accrued...
$4,936K
Refundable research income
tax credits
-$4,525K
Prepaid expenses and
other assets
-$1,201K
Stock-based compensation
$992K
Depreciation and
amortization
$719K
Accrued compensation
and employee...
$630K
Amortization in operating
lease right-of-use...
$158K
Net cash used in
operating activities
-$19,282K
Effect of exchange rate
changes on cash, cash...
-$766K
Net cash used in
investing activities
-$13K
Canceled cashflow
$13,161K
Net loss
-$30,995K
Purchases of property and
equipment
$13K
Accounts receivable
$502K
Deferred revenues
-$497K
Lease liabilities
-$449K
Buy us a coffee
SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)